Valuation: MacroGenics, Inc.

Market Cap 299M 262M 241M 224M 425M 28.51B 432M 2.89B 1.12B 14.01B 1.12B 1.1B 48.28B P/E 2026 *
-7.02x
P/E 2027 * -3.08x
Enterprise Value 299M 262M 241M 224M 425M 28.51B 432M 2.89B 1.12B 14.01B 1.12B 1.1B 48.28B EV / Sales 2026 *
1.82x
EV / Sales 2027 * 3.18x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+1.95%
1 week-2.08%
Current month+1.95%
1 month+12.14%
3 months+53.42%
6 months+192.55%
Current year+192.55%
1 week 4.5
Extreme 4.495
4.96
1 month 3.81
Extreme 3.81
5.08
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
28.88
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 71 01/07/2020
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

25,750 0.0405%
05-19Free

Director

25,750 0.0405%
05-19Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+1.95%-2.08%+222.60%-12.45% 299M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.78%+7.82%+71.43%+130.20% 24.58B
Weighted average by Cap. +2.46%+6.47%+59.26%+137.51%

Financials

2026 *2027 *
Net sales 164M 144M 132M 123M 233M 15.65B 237M 1.59B 616M 7.69B 617M 604M 26.51B 94.26M 82.4M 75.73M 70.59M 134M 8.97B 136M 909M 353M 4.41B 354M 346M 15.2B
Net income -18.31M -16M -14.71M -13.71M -26M -1.74B -26.39M -177M -68.63M -857M -68.71M -67.24M -2.95B -127M -111M -102M -95.13M -180M -12.1B -183M -1.23B -476M -5.95B -477M -467M -20.49B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
02/07/26 US$4.710 +1.95% 861,177
01/07/26 US$4.620 0.00% 763,302
30/06/26 US$4.620 -4.94% 832,393
29/06/26 US$4.860 +1.04% 1,364,698
26/06/26 US$4.810 +3.22% 8,516,839
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.710USD
Average target price
6.750USD
Spread / Average Target
+43.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock